Corpus overview


Overview

MeSH Disease

Human Phenotype

Encephalitis (7)

Headache (3)

Cough (3)

Stroke (2)

Myelitis (2)


Transmission

Seroprevalence
    displaying 1 - 7 records in total 7
    records per page




    The Incidence of SARS-COV-2 Manifestations in the Central Nervous System: A Rapid Review and Meta-Analysis

    Authors: Verena Mayr; Glechner Anna; Gerald Gartlehner; Irma Klerings; Peter Lackner

    doi:10.21203/rs.3.rs-44795/v1 Date: 2020-07-17 Source: ResearchSquare

    Background: Coronavirus disease MESHD 2019 (COVID-19) is caused by SARS-CoV-2 and presents itself mainly as a respiratory tract infection MESHD respiratory tract infection HP. However, reports of associated central nervous system (CNS) manifestations are increasing.Methods: We conducted this rapid review to determine the frequency of CNS manifestations of COVID-19 (CNS symptoms, acute cerebrovascular disease MESHD, and infectious/inflammatory CNS diseases MESHD) and to summarize the current evidence for direct invasion of the CNS by SARS-CoV-2. An information specialist searched Ovid MEDLINE, the CDC: COVID-19 Research Articles Downloadable and WHO COVID-19 Databases, CENTRAL, and Epistemonikos.org on May 13, 2020. Two reviewers screened abstracts and potentially relevant full-text publications independently. The data extraction, assessment of risk of bias,and certainty of evidence using GRADE was done by one reviewer and double-checked by another. If possible and reasonable, a meta-analysis was carried out.Results: We identified 13 relevant studies (four cohort studies, nine case studies) with a total of 866 COVID-19 patients.In a Chinese cohort, dizziness MESHD (16.8%; 36 of 214) and headache MESHD headache HP (13.1%; 28 of 214) were the most common CNS symptoms reported. A meta-analysis of four cohort studies including 851 COVID-19 patients showed an incidence of 3.3% (95% CI: 2.2–4.9) for ischemic stroke HP stroke MESHD (follow-up: one to five weeks). In 13 of 15 encephalitis MESHD encephalitis HP case studies, PCR testing of the cerebrospinal fluid did not detect any virus components.Conclusion: CNS manifestations occur frequently in patients with COVID-19. It is important to integrate neurologists into the multiprofessional COVID-19 treatment team to detect neurological complications early and to treat them correctly. 

    Neurological Complications of COVID-19: A Systematic Review of Literature

    Authors: Shitiz Sriwastava; Samiksha Srivastava; Saurabh Kataria; Violina Melnic; Amelia Adcock; Zubeda Sheikh

    doi:10.21203/rs.3.rs-35507/v1 Date: 2020-06-14 Source: ResearchSquare

    Background: To study the nature and frequency of occurrence of “significant” neurological complications in coronavirus disease MESHD-2019 (COVID-19) via a systematic review of the literature.Methods: We screened all articles resulting from a search of PubMed, Cochrane, Google Scholar and Scopus, using the keywords "COVID-19 and CNS", "SARS-CoV-2 and CNS”, “COVID-19 and neurological manifestation”, “SARS2 and neurological manifestation” and “COVID-19 and Brain” looking for reports of significant neurological manifestations that would potentially have an impact on the outcome.Results: Twenty-six articles met the inclusion criteria. The significant neurological diagnoses reported were stroke MESHD stroke HP, Guillain Barre Syndrome MESHD (GBS) and its variants, encephalitis MESHD encephalitis HP, seizures MESHD seizures HP, acute hemorrhagic necrotizing encephalopathy, acute HP acute disseminated encephalomyelitis MESHD (ADEM) and transverse myelitis MESHD myelitis HP. Although stroke MESHD stroke HP, predominantly ischemic, was observed in ~ 6% of COVID-19 patients from Wuhan, China, mortality in this cohort was 38%. Of the 24 pooled patients with reports of etiology, 17 had large vessel occlusions. GBS occurred in 5/1200 (0.4%) of the COVID-19 cohort from Italy. One of the six reported encephalitis MESHD encephalitis HP cases, the ADEM case and the report of transverse myelitis MESHD myelitis HP do not have data for conclusive diagnosis.Conclusion: The most frequent significant neurological association with COVID-19 is stroke MESHD stroke HP, predominantly ischemic. In a cohort from Wuhan, China, this was as frequent as ~ 6%, with a 38% mortality. Most common reported etiology is large vessel occlusion. Other reported significant neurological complications are GBS/variants, encephalitis MESHD encephalitis HP, seizures MESHD seizures HP and acute hemorrhagic necrotizing encephalopathy HP. The reports of ADEM and transverse myelitis MESHD myelitis HP lacked diagnostically conclusive data.

    Bipallidal Lesions in a COVID-19 Patient: A Case Report and Brief Review of Literature

    Authors: Sudhat Ashok; Kalyan Shastri; L. Beryl Guterman; Lee R. Guterman

    doi:10.21203/rs.3.rs-34525/v1 Date: 2020-06-09 Source: ResearchSquare

    BackgroundAltered mentation in COVID-19 patients can be a function of any number of metabolic abnormalities associated with the infection MESHD. Here we present the case of an encephalopathic COVID-19 patient with bilateral globus pallidus lesions. While imaging abnormalities involving basal ganglia have been reported in encephalitis MESHD encephalitis HP caused by neuroinvasive flaviviruses, the bipallidal lesions noted here likely resulted from hypoxic-ischemic brain injury MESHD.Case PresentationA 51-year-old African American woman was found unresponsive at home by her fiancé. She had been complaining of shortness of breath and cough MESHD cough HP for three days. She is a former smoker with past medical history of hypertension MESHD hypertension HP, nephropathy HP, and bipolar disorder. Upon examination, she was alert but nonverbal, following commands inconsistently, and unable to move extremities against gravity. After several minutes, she was able to state her name but kept repeating it in response to all questions. Chest radiograph revealed bilateral lung infiltrates. CT of the head showed hypodensities in bilateral globus pallidi. A non-contrast MRI of the brain showed symmetric restricted diffusion and FLAIR hyperintense signal changes in bilateral globus pallidi. Abnormal SWI signal seen in bilateral globus pallidi likely represents mineralization or hemosiderin. There were no striatal or thalamic lesions. Major intracranial arteries were widely patent.The patient later tested positive for 2019-nCoV using real-time PCR assay, and was transferred to our COVID-19 designated hospital campus. Thereafter, she had waxing and waning mentation. Repeat CT imaging 11 days after the first scan demonstrated resolution of the bipallidal hypodensities. The patient was recently discharged to a subacute rehab facility but is still experiencing confusion MESHD confusion HP.ConclusionsAs we come across neurological manifestations of COVID-19, we believe neuroimaging is likely to play an important role in establishing if central nervous system involvement is invariably due to indirect mechanisms such as metabolic or hypoxic-ischemic brain injury MESHD or if direct neuroinvasive disease MESHD is a possibility, as with certain viruses.

    First Case Of SAR TRANS-Coronavirus-2 Sequencing In The Cerebrospinal Fluid Of A Patient With Suspected CNS Demyelinating Disease MESHD

    Authors: Renan Domingues; Maria Cássia Mendes-Correa; Fernando Brunale Vilela de Moura Leite; Ester Cerdeira Sabino; Ingra M Claro; Noely Evangelista Ferreira; Camila Malta Romano; Jaqueline Goes de Jesus; Daniel Wagner de Castro Lima Santos; Diego Zanotti Salarini; Carlos Senne

    doi:10.21203/rs.3.rs-31801/v1 Date: 2020-05-26 Source: ResearchSquare

    The association between coronaviruses and central nervous system (CNS) demyelinating lesions has been previously shown. However, no case has been described of an association between the novel coronavirus (SARS-COV-2) and CNS demyelinating disease MESHD so far. SARS-COV-2 was previously detected in cerebrospinal fluid (CSF) sample of a patient with encephalitis MESHD encephalitis HP. However, the virus identity was not confirmed by deep sequencing of SARS-COV-2 detected in the CSF. Here, we report a case of a patient with mild respiratory symptoms and neurological manifestations compatible with Clinically Isolated Syndrome MESHD. The viral genome of SARS-COV-2 was detected and sequenced in CSF with 99.74 to 100% similarity between the patient virus and worldwide sequences. This report suggests a possible association of SARS COV-2 infection MESHD with neurological symptoms of demyelinating disease MESHD, even in the absence of relevant upper respiratory tract infection MESHD respiratory tract infection HP signs.

    Neurological Involvement of Coronavirus Disease MESHD 2019: A Systematic Review

    Authors: Malik Ghannam; Qasem Alshaer; Mustafa Al-Chalabi; Lara Zakarna; Jetter Robertson; Georgios Manousakis

    doi:10.21203/rs.3.rs-31183/v1 Date: 2020-05-23 Source: ResearchSquare

    Background: In December 2019, unexplained cases of pneumonia MESHD pneumonia HP emerged in Wuhan, China, which were found to be secondary to the novel coronavirus SARS-CoV-2. On March 11, 2020, the WHO declared the Coronavirus Disease MESHD 2019 (COVID-2019) outbreak, a pandemic. Although the most common presentations of COVID-19 are fever MESHD fever HP, cough MESHD cough HP and shortness of breath, several clinical observations indicate that COVID-19 does affect the central and peripheral nervous system.  Methods: We conducted a systematic literature search from December 01, 2019 to May 14, 2020 using multiple combinations of keywords from PubMed and Ovid Medline databases according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We included articles with cases of COVID-19 that were evident for neurological involvement.  Results: We were able to identify 82 cases of COVID-19 with neurological complications. The mean age TRANS was 62.28 years. 37.8% of the patients were women (n = 31). 48.8% of the patients (n=40) had cerebrovascular insults, 28% (n=23) had neuromuscular disorders, 18.3% of the patients (n=15) had encephalitis MESHD encephalitis HP or encephalopathy HP, and 2.4% (n=2) presented with status epilepticus MESHD status epilepticus HP. Conclusions: Neurological manifestations of COVID-19 infection MESHD are not rare, especially large vessel stroke MESHD stroke HP, Guillain barre syndrome MESHD and meningoencephalitis MESHD. Moving forward, further studies are needed to clarify the prevalence SERO of the neurological complications of COVID-19, investigate their biological backgrounds, and test treatment options. Physicians should be cautious not to overlook other neurological diagnoses that can mimic COVID-19 during the pandemic.

    Ageusia MESHD and Anosmia HP, a Common Aign of COVID-19? A Case Series from Four Countries

    Authors: Jair Vargas-Gandica; Daniel Winter; Rainer Schnippe; Andrea G. Rodriguez-Morales; Johana Mondragon; Juan Pablo Escalera-Antezana; María del Pilar Trelles-Thorne; D. Katterine Bonilla-Aldana; Alfonso J. Rodriguez-Morales; Alberto Paniz-Mondolfi

    id:10.20944/preprints202005.0327.v1 Date: 2020-05-20 Source: Preprints.org

    Over the course of the pandemic due to the severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2), multiple new clinical manifestations, as the consequence of the tropism of the virus, have been recognized. That includes now the neurological manifestations and conditions, such as headache MESHD headache HP, encephalitis MESHD encephalitis HP, as well as olfactory and taste disorders MESHD. We present a series of ten cases of RT-PCR confirmed SARS-CoV-2 infected patients diagnosed with viral-associated olfactory and taste loss from four different countries.

    Neurological Manifestations and Complications of COVID-19: A Literature Review

    Authors: Imran Ahmad; Farooq Azam Rathore

    id:10.20944/preprints202004.0453.v1 Date: 2020-04-25 Source: Preprints.org

    The Coronavirus disease MESHD due to SARS-CoV-2 emerged in Wuhan city, China in December 2019 and rapidly spread more than 200 countries as a global health pandemic. There are more 3 million confirmed cases TRANS and around 207,000 fatalities. The primary manifestation is respiratory and cardiac but neurological manifestations are being reported in the literature as case reports and case series. The most common reported symptoms to include headache MESHD headache HP and dizziness MESHD followed by encephalopathy HP and delirium MESHD delirium HP. Among the complications noted are Cerebrovascular accident, Guillian barre syndrome MESHD, acute transverse myelitis MESHD myelitis HP, and acute encephalitis MESHD encephalitis HP. The most common peripheral manifestation was hyposmia HP. It is further noted that sometimes the neurological manifestations can precede the typical features like fever MESHD fever HP and cough MESHD cough HP and later on typical manifestations develop in these patients. Hence a high index of suspicion is required for timely diagnosis and isolation of cases to prevent the spread in neurology wards. We present a narrative review of the neurological manifestations and complications of COVID-19. Our aim is to update the neurologists and physicians working with suspected cases of COVID-19 about the possible neurological presentations and the probable neurological complications resulting from this novel virus infection MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.